Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Finished Goods (2023 - 2025)

Verrica Pharmaceuticals has reported Finished Goods over the past 3 years, most recently at $991000.0 for Q2 2025.

  • Quarterly results put Finished Goods at $991000.0 for Q2 2025, up 13.65% from a year ago — trailing twelve months through Jun 2025 was $991000.0 (up 13.65% YoY), and the annual figure for FY2024 was $717000.0, up 523.48%.
  • Finished Goods for Q2 2025 was $991000.0 at Verrica Pharmaceuticals, down from $1.2 million in the prior quarter.
  • Over the last five years, Finished Goods for VRCA hit a ceiling of $1.2 million in Q1 2025 and a floor of $115000.0 in Q4 2023.
  • Median Finished Goods over the past 3 years was $699000.0 (2024), compared with a mean of $674875.0.
  • Biggest five-year swings in Finished Goods: soared 523.48% in 2024 and later grew 13.65% in 2025.
  • Verrica Pharmaceuticals' Finished Goods stood at $115000.0 in 2023, then soared by 523.48% to $717000.0 in 2024, then soared by 38.21% to $991000.0 in 2025.
  • The last three reported values for Finished Goods were $991000.0 (Q2 2025), $1.2 million (Q1 2025), and $717000.0 (Q4 2024) per Business Quant data.